NasdaqCM - Delayed Quote USD

NexImmune, Inc. (NEXI)

3.3700 -0.0400 (-1.17%)
At close: April 26 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
32,282.8540
32,282.8540
63,082.8890
53,255.7820
27,851.4330
Operating Income
-32,282.8540
-32,282.8540
-63,082.8890
-53,255.7820
-27,851.4330
Net Non Operating Interest Income Expense
698.3950
698.3950
664.3720
-852.8150
-1,662.0570
Other Income Expense
-759.9340
-759.9340
-87.6820
3,207.0890
-352.5070
Pretax Income
-32,344.3930
-32,344.3930
-62,506.1990
-50,901.5080
-29,865.9970
Net Income Common Stockholders
-32,344.3930
-32,344.3930
-62,506.1990
-51,279.0700
-33,147.1910
Diluted NI Available to Com Stockholders
-32,344.3930
-32,344.3930
-62,506.1990
-51,279.0700
-33,147.1910
Basic EPS
-30.82
-30.82
-64.95
-63.50
-41.92
Diluted EPS
-30.82
-30.82
-64.95
-63.50
-41.92
Basic Average Shares
1,049.4680
1,049.4680
962.3640
807.4450
790.6950
Diluted Average Shares
1,049.4680
1,049.4680
962.3640
807.4450
790.6950
Total Operating Income as Reported
-32,973.6220
-32,973.6220
-63,082.8890
-53,255.7820
-27,851.4330
Total Expenses
32,282.8540
32,282.8540
63,082.8890
53,255.7820
27,851.4330
Net Income from Continuing & Discontinued Operation
-32,344.3930
-32,344.3930
-62,506.1990
-50,901.5080
-29,865.9970
Normalized Income
-31,653.6250
-31,653.6250
-62,506.1990
-54,170.0040
-29,423.7130
Interest Income
698.3950
698.3950
664.3720
52.5110
20.8370
Interest Expense
--
--
--
905.3260
1,682.8940
Net Interest Income
698.3950
698.3950
664.3720
-852.8150
-1,662.0570
EBIT
-32,282.8540
-32,282.8540
-63,082.8890
-49,996.1820
-28,183.1030
EBITDA
-31,257.8810
-31,257.8810
-62,088.0970
-49,125.8970
-27,564.1130
Reconciled Depreciation
1,024.9730
1,024.9730
994.7920
870.2850
618.9900
Net Income from Continuing Operation Net Minority Interest
-32,344.3930
-32,344.3930
-62,506.1990
-50,901.5080
-29,865.9970
Total Unusual Items Excluding Goodwill
-690.7680
-690.7680
--
3,268.4960
-442.2840
Total Unusual Items
-690.7680
-690.7680
--
3,268.4960
-442.2840
Normalized EBITDA
-30,567.1130
-30,567.1130
-62,088.0970
-52,394.3930
-27,121.8290
12/31/2020 - 2/12/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SPRC SciSparc Ltd.
1.3200
+4.76%
 
ENSC Ensysce Biosciences, Inc.
0.5842
+1.69%
 
REVB Revelation Biosciences, Inc.
2.1800
+2.83%
 
PBLA Panbela Therapeutics, Inc.
0.4100
-6.82%
 
CING Cingulate Inc.
0.8801
+1.71%
 
FNCH Finch Therapeutics Group, Inc.
2.3200
+3.11%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
ADTX Aditxt, Inc.
2.3900
-5.53%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
FWBI First Wave BioPharma, Inc.
2.7400
+0.37%